by Maria Zannes | Mar 6, 2019 | Press Releases
MARCH 6, 2019 (San Antonio, TX) Healthcare innovators Lyfebulb and Helsinn selected bioAffinity Technologies, a privately held biotech company developing diagnostics and therapeutics for cancer, as one of 10 finalists for the second annual in Oncology. The Innovation...
by Maria Zannes | Mar 6, 2019 | News
BioAffinity Technologies is proud to be named a finalist in the Lyfebulb Helsinn 2019 Innovation Summit in Oncology. Lyfebulb-Helsinn Innovation Summit March 18 and 19, 2019 Monaco, Principality of Monaco Ten finalists will compete at the second annual...
by Maria Zannes | Feb 5, 2019 | Press Releases
FEBRUARY 4, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, announced that the Canadian Intellectual Property Office has awarded a patent expanding the Company’s claims associated with its proprietary CyPath© technology for the early...
by Maria Zannes | Oct 23, 2018 | Press Releases
OCTOBER 23, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced that the South Texas Veterans Health Care System (STVHCS), which is affiliated with the federal Department of Veterans Affairs (VA) health care system, will...
by Maria Zannes | Oct 12, 2018 | News
OCTOBER 10, 2018 As published in Genome Web’s 360Dx NEW YORK, NY – BioAffinity Technologies today said that it has inked a licensing agreement with Precision Pathology Services for the continued development and commercial sale of its CyPath Lung assay as a...
